Colon Cancer Clinical Trial

Improving Followup of Abnormal Colon Cancer Screening Tests

Summary

The purpose of this study is to determine whether direct mailings to patients with positive fecal occult blood tests can increase rates of performing followup colonoscopy.

View Full Description

Full Description

Screening programs using the fecal occult blood test (FOBT) have demonstrated a significant reduction in colorectal cancer mortality, although only when accompanied by a complete diagnostic evaluation of the colon in the setting of a positive result. 90% of patients with a positive FOBT result have completed a subsequent colonoscopy within Harvard Vanguard Medical Associates. This project will use a pre-post study design to increase the rate of followup colonoscopy in the setting of positive FOBT results. Patients in the intervention group will receive a personalized mailing highlighting their positive result and need for colonoscopy, followed by telephone outreach from a centralized gastroenterology scheduling office. The primary outcome will be the performance of colonoscopy, however we will also perform chart reviews to identify predictors of completing appropriate followup.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Patients with positive fecal occult blood test during 2004, 2005, and 2006; and no colonoscopy following this test result

Exclusion Criteria:

Patients with active cardiopulmonary disease or limited life expectancy due to severe illness such as malignancy
Colonoscopy within 5 years prior to positive fecal occult blood test
Age > 80 years

Study is for people with:

Colon Cancer

Estimated Enrollment:

70

Study ID:

NCT00436137

Recruitment Status:

Completed

Sponsor:

Harvard Vanguard Medical Associates

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Harvard Vanguard Medical Associates
Newton Massachusetts, 02466, United States

How clear is this clinincal trial information?

Study is for people with:

Colon Cancer

Estimated Enrollment:

70

Study ID:

NCT00436137

Recruitment Status:

Completed

Sponsor:


Harvard Vanguard Medical Associates

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider